Ikke-kategoriseret Arkiv - Page 4 of 7

Cantargias valberedning föreslår ny styrelseledamot

22/09/2020

Cantargias valberedning föreslår ny styrelseledamot Valberedningen i Cantargia AB (publ), som består av Sten Verland (partner i Sunstone Life Science Ventures, ordförande), Jannis Kitsakis (Fjärde AP-fonden), Alexander Mata (Alecta Pensionförsäkring, ömsesidigt) och...

Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020.

16/09/2020

Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020. Orphazyme A/S (ORPHA.CO), a...

Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe

07/09/2020

Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe Orphazyme A/S (ORPHA.CO) (the “Company”), a...

F2G closes USD 60.8 Million financing to fund late stage development of novel mechanism antifungal agent

13/08/2020

F2G closes USD 60.8 Million financing to fund late stage development of novel mechanism antifungal agent F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that it has secured US $60.8...

Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C

11/08/2020

Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize...

Orphazyme to collaborate with The Michael J. Fox Foundation on Parkinson’s disease research

17/07/2020

Orphazyme to collaborate with The Michael J. Fox Foundation on Parkinson’s disease research Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the...

Cantargias valberedning föreslår ny styrelseledamot

Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020.

Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe

F2G closes USD 60.8 Million financing to fund late stage development of novel mechanism antifungal agent

Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C

Orphazyme to collaborate with The Michael J. Fox Foundation on Parkinson’s disease research

Recent Posts

Recent Comments

Archives

Categories

Meta